GeneDx is a genomic diagnostics company with 84% revenue growth score and strong analyst consensus, but quality below the investment minimum at 3.9 out of 10, a 30% short interest, and a massive single-quarter earnings miss of -1,408% make this a high-risk situation requiring fundamental stabilization before new entry.
Thesis pillars
- Quality Just Below Floor→Stable
- Severe Earnings Miss Recent→Stable
- High Short Interest And Put Call→Stable
- +1 more pillar — see the Why tab for full reasoning
GeneDx Holdings Corp. (WGS) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $69.44: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend.
GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases, drawing on a dataset of over 2.5 million tests including more than 1 million exomes and genomes. Revenue derives almost entirely from diagnostic test reports, with... Read more
Sell if holding. Engine safety override at $69.44: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 71. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, no SEC red flags, news boost analyst 0.70, earnings proximity 29d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
Recent developments
updated 2026-06-29Recent Developments — GeneDx Holdings Corp.
Latest news
- NEWS Insider sells Class A stock at WGS (NASDAQ: WGS) — multiple lots reported - Stock Titan — Stock Titan negative
- NEWS Earnings Preview: WGS to Report Financial Results Post-market on May 04 - Moomoo — Moomoo neutral
- NEWS Jefferies reiterates GeneDx stock rating citing market penetration - Investing.com — Investing.com positive
- NEWS WGS Stock Slumps After Hours As Firm Predicts Lower Test Volume For Year - Stocktwits — Stocktwits negative
- NEWS Craig-Hallum reaffirms buy on GeneDx (WGS) with $153 price target - MSN — MSN positive
Generated 2026-06-29T23:58:56Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductdiagnostic test reports10-K Item 1: 'Substantially all of our revenue for the year ended December 31, 2025 was derived from diagnostic test reports'
- HIGHSuppliersingle suppliers for laboratory instruments and materials10-K Item 1A: 'We rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -17.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $69.44: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: High short interest: 39%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $64.60. Score 5.5/10, moderate confidence.
Take-profit target: $69.92 (+0.7% upside). Prior stop was $64.60. Stop-loss: $64.60.
Concentration risk — Product: diagnostic test reports; Concentration risk — Supplier: single suppliers for laboratory instruments and materials; Target reached (-1.7% upside).
GeneDx Holdings Corp. trades at a P/E of N/A (forward 56.7). TrendMatrix value score: 6.0/10. Verdict: Sell.
13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $78.
What does GeneDx Holdings Corp. do?GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases,...
GeneDx provides exome and whole genome sequencing diagnostic tests focused on pediatric rare and genetic diseases, drawing on a dataset of over 2.5 million tests including more than 1 million exomes and genomes. Revenue derives almost entirely from diagnostic test reports, with approximately 1.5% from outside the United States; the company employs nearly 1,300 people.